EDGE
Book a demo
Log In
All Updates

All Updates

icon
Filter
Last week:
FDA approval
FDA approves Reunion Neuroscience’s IND submission for RE104
Psychedelic Medicine
Sep 18, 2023
Funding
Clearmind Medicine announces USD 2.3 million public offering
Psychedelic Medicine
Sep 14, 2023
Partnerships
Clearmind Medicine partners with Johns Hopkins University for clinical research
Psychedelic Medicine
Sep 6, 2023
Management news
PharmaDrug appoints Robert J. Steen as new CEO
Psychedelic Medicine
Sep 6, 2023
Funding
Optimi Health secures CAD 1 million via second tranche of debt financing
Psychedelic Medicine
Sep 5, 2023
M&A
Otsuka Pharmaceutical acquires Mindset Pharma for CAD 80 million
Psychedelic Medicine
Aug 31, 2023
Partnerships
Filament Health enters licensing agreement with Reset Pharma
Psychedelic Medicine
Aug 31, 2023
Product updates
NeoLumina Bioscience launches from stealth; initiates funding activity
Psychedelic Medicine
Aug 30, 2023
M&A
Silo Wellness to acquire Kaya for CAD 43.3 million to expand globally
Psychedelic Medicine
Aug 29, 2023
M&A
Cybin to acquire Small Pharma to strengthen psychedelic portfolio
Psychedelic Medicine
Aug 28, 2023
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.